GABPα inhibits tumor progression and angiogenesis via a novel 18-bp indel within <i>VEGF</i> promoter in breast cancer.
Our findings provide insights into angiogenic targeted strategy aiming at GABPα-VEGF axis in clinical diagnosis and therapy of breast cancer.
Authors
- Jihua Chen (ORCID: https://orcid.org/0000-0001-6879-5936)
- Zhenrong Wang (ORCID: https://orcid.org/0000-0002-7705-3472)
- Yao Xu (ORCID: https://orcid.org/0009-0006-3504-0354)
- Hui Guo (ORCID: https://orcid.org/0009-0000-4110-5587)
- Xiaotong Deng (ORCID: https://orcid.org/0000-0001-9216-5280)
- Mengyi Wang (ORCID: https://orcid.org/0000-0002-9348-6876)
- Qi Zhou (ORCID: https://orcid.org/0000-0003-4567-6525)
- Yue Han (ORCID: https://orcid.org/0000-0003-2848-3350)
- Fan Li
Institutions
- Wuhan Institute of Bioengineering (CN)
- Wuhan University of Science and Technology (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-12-01
- DOI
- https://doi.org/10.3233/cbm-230541
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00